Transthyretin Amyloid Cardiomyopathy - Pipeline Inisght, 2021

This “Transthyretin Amyloid Cardiomyopathy - Pipeline Insight, 2021,” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Transthyretin Amyloid Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Transthyretin Amyloid Cardiomyopathy Understanding

Transthyretin Amyloid Cardiomyopathy: Overview

Transthyretin Amyloid Cardiomyopathy (ATTR-CM) is an underdiagnosed and potentially fatal disease. It's characterized by deposits of amyloid protein fibrils in the walls of the left ventricle, the main pumping chamber of the heart. In ATTR-CM, the amyloid protein is made of transthyretin. The amyloid protein deposits cause the heart walls to become stiff, resulting in the inability of the left ventricle to: 1. properly relax and fill with blood 2. Adequately squeeze to pump blood out of the heart. Due to genetic mutation or aging, the transthyretin doesn't assemble normally these abnormal proteins then clump together and shape themselves into amyloid fibrils. The fibrils travel through the bloodstream and are deposited in many organs, including the heart. As fibrils accumulate in the tissue, they thicken and stiffen the myocardium or wall of the heart. This causes a cardiomyopathy and, ultimately, heart failure. The diagnosis may be suspected because of typical symptoms and the results of a routine cardiac test - an electrocardiogram or echocardiogram. Once suspected, more specialized tests are needed to confirm the diagnosis. There are several promising new therapies for ATTR-CM on the horizon. Medications are approved for hereditary transthyretin amyloidosis affecting the nerves, causing a condition called neuropathy.

"Transthyretin Amyloid Cardiomyopathy - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Transthyretin Amyloid Cardiomyopathy pipeline landscape is provided which includes the disease overview and Transthyretin Amyloid Cardiomyopathy treatment guidelines. The assessment part of the report embraces, in depth Transthyretin Amyloid Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Transthyretin Amyloid Cardiomyopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Transthyretin Amyloid Cardiomyopathy R&D. The therapies under development are focused on novel approaches to treat/improve Transthyretin Amyloid Cardiomyopathy.

Transthyretin Amyloid Cardiomyopathy Emerging Drugs Chapters

This segment of the Transthyretin Amyloid Cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Transthyretin Amyloid Cardiomyopathy Emerging Drugs

AKCEA-TTR-LRx: Ionis Pharmaceuticals

AKCEA-TTR-LRx is an antisense drug developed using Ionis' proprietary LIgand Conjugated Antisense (LICA) technology platform and is designed to inhibit production of TTR. It was discovered by Ionis and is being co-developed by Ionis and Akcea. CARDIO-TTRansform is a global, double-blind, randomized, placebo-controlled Phase III cardiovascular outcome study. It is designed to compare AKCEA-TTR-LRx to placebo in patients with both wild type and hereditary ATTR cardiomyopathy who are on the current available standard of care.

ALXN2060: Alexion Pharmaceuticals/Eidos Therapeutics

Alexion holds an exclusive license to develop and commercialize ALXN2060 (AG10) in Japan. Eidos is currently evaluating AG10 in two Phase III studies in the US and Europe - one for ATTR cardiomyopathy (ATTR-CM) and one for ATTR polyneuropathy (ATTR-PN). Alexion is conducting a Phase III bridging study of ALXN2060 for patients with ATTR-CM in Japan.

Transthyretin Amyloid Cardiomyopathy: Therapeutic Assessment

This segment of the report provides insights about the different Transthyretin Amyloid Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Transthyretin Amyloid Cardiomyopathy

There are approx. 8+ key companies which are developing the therapies for Transthyretin Amyloid Cardiomyopathy. The companies which have their Transthyretin Amyloid Cardiomyopathy drug candidates in the most advanced stage, i.e. Phase III include, Ionis Pharmaceuticals.

Phases

This report covers around 8+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Transthyretin Amyloid Cardiomyopathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Transthyretin Amyloid Cardiomyopathy: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Transthyretin Amyloid Cardiomyopathy therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Transthyretin Amyloid Cardiomyopathy drugs.

Transthyretin Amyloid Cardiomyopathy Report Insights

• Transthyretin Amyloid Cardiomyopathy Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Transthyretin Amyloid Cardiomyopathy Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Transthyretin Amyloid Cardiomyopathy drugs?
• How many Transthyretin Amyloid Cardiomyopathy drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Transthyretin Amyloid Cardiomyopathy?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Transthyretin Amyloid Cardiomyopathy therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Transthyretin Amyloid Cardiomyopathy and their status?
• What are the key designations that have been granted to the emerging drugs?

This product will be delivered within 2 business days.